scholarly journals Combination of multiple gene markers to detect circulating tumor cells in the peripheral blood of patients with non-small cell lung cancer using real-time PCR

2015 ◽  
Vol 14 (4) ◽  
pp. 13033-13040 ◽  
Author(s):  
M. Ding ◽  
X. Li ◽  
T. Qiu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Real Time ◽  
Tumor Cells ◽  
Real Time Pcr ◽  
Peripheral Blood ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gene Markers ◽  
Multiple Gene

scholarly journals Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer

2016 ◽  
Vol 62 (6) ◽  
pp. 638-644
Author(s):  
O.I. Brovkina ◽  
M.G. Gordiev ◽  
A.N. Toropovskiy ◽  
D.S. Khodyrev ◽  
R.F. Enikeev ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Real Time ◽  
Cell Lung Cancer ◽  
Real Time Pcr ◽  
Test System ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Egfr Gene

The presence of activating mutations in the EGFR gene influences cell proliferation, angiogenesis, and increases metastatic ability; it has a significant impact on the choice of medical therapy of non-small cell lung cancer (NSCLC). The use of targeted therapy with tyrosine kinase inhibitors requires performance of appropriate genetic tests. The aim of this study was to design a real-time PCR-based diagnostic kit for fast and cheap of EGFR mutations testing in paraffin blocks and plasma, and kit validation using samples from patients with NSCLC, and also comparative estimation of diagnostic features of real-time PCR with wild type blocking and digital PCR for mutation testing in blood plasma. The study included 156 patients with various types of adenocarcinoma differentiation. It was designed a simple and efficient real-time PCR-based method of detecting L858R activating mutation and del19 deletion in the EGFR gene for DNA isolated from paraffin blocks. Kit for EGFR mutations was validated using 411 samples of paraffin blocks. The proposed system showed high efficiency for DNA testing from paraffin blocks: a concordance with results of testing with therascreen® EGFR RGQ PCR Kit (`Qiagen`, Germany) was 100%. It has been shown the possibility of using this test system for the detection of mutations in plasma

scholarly journals Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer

PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181211 ◽  
Author(s):  
Ippokratis Messaritakis ◽  
Eleni Politaki ◽  
Athanasios Kotsakis ◽  
Eleftheria-Kleio Dermitzaki ◽  
Filippos Koinis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Small Cell ◽  
Phenotypic Characterization ◽  
Small Cell Lung

scholarly journals Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3394
Author(s):  
Hsin-Lun Lee ◽  
Jeng-Fong Chiou ◽  
Peng-Yuan Wang ◽  
Long-Sheng Lu ◽  
Chia-Ning Shen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Drug Sensitivity ◽  
Ex Vivo ◽  
Small Cell ◽  
Small Cell Lung ◽  
Blood Samples

Small cell lung cancer (SCLC) represents one of the most aggressive malignancies among cancer types. Not only tumor sample availability is limited, but also the ability for tumor cells to rapidly acquire drug resistance are the rate-limiting bottlenecks for overall survival in current clinical settings. A liquid biopsy capable of capturing and enriching circulating tumor cells (CTCs), together with the possibility of drug screening, is a promising solution. Here, we illustrate the development of a highly efficient ex vivo CTC expansion system based on binary colloidal crystals substrate. Clinical samples were enrolled from 22 patients with SCLC in the study. The CTCs were enriched and expanded from the collected peripheral blood samples. Expanded cells were analyzed for protein expression and observed for drug sensitivity with the use of immunofluorescence and ATP titer evaluation, respectively. Successful CTC spheroid proliferation was established after 4 weeks within 82% of all the collected peripheral blood samples from enrolled patients. Upon immunofluorescence analysis, the enriched cells showed positive markers for EpCAM, TTF-1, synaptophysin and negative for CD45. Additionally, the expanded CTCs demonstrated marked heterogeneity in the expression of E-cadherin and N-cadherin. In a preliminary case series, the drug sensitivity of patient-derived CTC to cisplatin and etoposide was studied to see the correlation with the corresponding therapeutic outcome. In conclusion, our study demonstrates that it is possible to efficiently expand CTCs from SCLC within a clinically relevant time frame; the biomarker information generated from enriched CTCs can assist the selection of effective drugs and improve disease outcome.

Sign in / Sign up

Export Citation Format

Share Document